CSIMarket Company Name, Ticker, Industry, else..
 
Alkermes Plc   (NASDAQ: ALKS)
Other Ticker:  
 
 
Price: $31.1900 $-0.56 -1.764%
Day's High: $31.735 Week Perf: 5.84 %
Day's Low: $ 30.97 30 Day Perf: 4.98 %
Volume (M): 1,666 52 Wk High: $ 32.88
Volume (M$): $ 51,959 52 Wk Avg: $27.08
Open: $31.52 52 Wk Low: $22.90



 Market Capitalization (Millions $) 5,210
 Shares Outstanding (Millions) 167
 Employees 2,100
 Revenues (TTM) (Millions $) 1,505
 Net Income (TTM) (Millions $) 333
 Cash Flow (TTM) (Millions $) -251
 Capital Exp. (TTM) (Millions $) 41

Alkermes Plc
Alkermes Plc is a biopharmaceutical company that specializes in developing innovative medicines to address unmet medical needs in large therapeutic categories. The company was founded in 1987 and is headquartered in Dublin, Ireland, with additional operations and research facilities in the United States and Europe.

Alkermes is focused on developing treatments for serious and chronic diseases including addiction, schizophrenia, opioid use disorder, and CNS disorders. The company offers a broad range of products and technologies that enable the development of novel therapies, including drug delivery systems, manufacturing technologies, and analytical capabilities.

The company's product portfolio includes VIVITROL for Alcohol Dependence, ARISTADA for Schizophrenia, RISPERDAL CONSTA for Schizophrenia and Bipolar Disorder, and BYDUREON for Type 2 Diabetes, among others. Alkermes has also been actively pursuing the development of new treatments for opioid addiction and overdose, including ALKS 5461 and ALKS 3831.

Alkermes has a highly experienced research and development team that is dedicated to advancing the science of drug development. The company is committed to investing in new technologies and platforms that can help to accelerate the pace of discovery and bring new treatments to patients in need.

Alkermes Plc is a publicly traded company and is listed on the NASDAQ stock exchange under the ticker symbol "ALKS". The company has a strong track record of growth and continues to expand its global presence through strategic partnerships, acquisitions, and collaborations.


   Company Address: Connaught House Dublin 4 0
   Company Phone Number: 1-772-8000   Stock Exchange / Ticker: NASDAQ ALKS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACAD      % 
AMRX      % 
BMRN      % 
HRMY      % 
ITCI      % 
LLY      % 
• View Complete Report
   



Alkermes Plc

Alkermes Plc: Surging Profits Amidst the Changing Tides of Pharmaceutical Industry



Alkermes Plc, a major player in the pharmaceutical preparations industry, has recently reported its financial results for the third quarter of fiscal year 2023. With positive bottom-line growth, increased revenue, improved profit margins, and notable developments in key financial indicators, the company appears to be on a positive trajectory. This article aims to analyze the impact of these results and explore the potential implications for Alkermes Plc moving forward.
1. Strong Financial Performance:
During the July to September 30, 2023 fiscal interval, Alkermes Plc achieved positive bottom-line growth, with a profit of $0.28 per share compared to a loss of $-0.39 per share in the same period last year. This indicates a significant improvement in the company's financial position and reflects efficient cost management and operational effectiveness.
Alkermes Plc

Alkermes Plc Showcases Remarkable 123.517% Revenue Jump Despite EPS Downturn in Q2 2023

Alkermes Plc: Strong Revenue Growth and Improved Profit Margins Boost Investor Confidence
Alkermes Plc, a leading biopharmaceutical company, has reported impressive financial results for the period ending June 30, 2023, showcasing a remarkable revenue growth of 123.517% year on year to reach $617.40 million. This substantial increase in revenue was driven by a doubling of revenue by 114.676%, reaching $287.60 million, compared to the previous reporting season.
One of the most significant developments for Alkermes Plc was the turnaround in income, as the company exhibited earnings per share of $1.38, in stark contrast to the preceding reporting season when net profit per share was at $-0.25. This positive shift demonstrates the company's ability to generate substantial profits while meeting market expectations.






Alkermes Plc's Segments
VIVITROL    30.05 % of total Revenue
ARISTADA and ARISTADA INITIO    22.39 % of total Revenue
LYBALVI    19.75 % of total Revenue
Product sales net    72.19 % of total Revenue
Manufacturing Revenue    4.22 % of total Revenue
Manufacturing Revenue VUMERITY    2.31 % of total Revenue
Manufacturing Revenue Other    1.9 % of total Revenue
Royalty    23.59 % of total Revenue
Royalty Long-Acting INVEGA Products    15.46 % of total Revenue
Royalty VUMERITY    6.3 % of total Revenue
Royalty Other    1.83 % of total Revenue
Manufacturing and royalty revenues    27.81 % of total Revenue
Manufacturing and royalty revenues Long-Acting INVEGA Products    15.46 % of total Revenue
Manufacturing and royalty revenues VUMERITY    8.61 % of total Revenue
Manufacturing and royalty revenues Other    3.73 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com